Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer.

Abstract

BACKGROUND:

Typhlitis is being recognized with increasing frequency as a serious complication of aggressive chemotherapy for hematologic and solid malignancies.

METHODS:

In this report the authors describe two cases of typhlitis in patients with metastatic breast cancer treated with taxol and doxorubicin.

RESULTS:

Both cases occurred during the first cycle of treatment with taxol (180 mg/m2) and doxorubicin (75 mg/m2), being given simultaneously as 72-hour continuous intravenous infusions.

CONCLUSION:

Two cases of typhlitis have occurred after combined treatment with taxol and doxorubicin, while typhlitis has not been described after treatment with either drug alone.

• Authors: B C Pestalozzi, G A Sotos, P L Choyke, J S Fisherman, K H Cowan, J A O'Shaughnessy
• Journal: Cancer (Cancer) Vol. 71 Issue 5 Pg. 1797-800 (Mar 01 1993) ISSN: 0008-543X [Print] United States
• PMID: 8095437 (Publication Type: Case Reports, Journal Article)

Chemical References

• Doxorubicin
• Paclitaxel

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Breast Neoplasms (drug therapy)
• Carcinoma (drug therapy, metabolism)
• Carcinoma, Intraductal, Noninfiltrating (drug therapy, metabolism)
• Cecal Diseases (chemically induced)
• Doxorubicin (administration & dosage, adverse effects)
• Female
• Humans
• Inflammation (chemically induced)
• Lymphatic Metastasis
• Middle Aged
• Paclitaxel (administration & dosage, adverse effects)